Fig. 1: Overview of the samples and study design.
From: Polygenic heterogeneity in antidepressant treatment and placebo response
The clinical test sample included 2191 genotyped MDD patients treated with vortioxetine or placebo from 7 randomized, double-blind, placebo-controlled clinical trials. 907 vortioxetine-treated patients and 455 placebo-treated patients of European genetic ancestry passed genotyping quality control (QC). Response was quantified using different clinical scales and sub-scales, resulting in 6 response measures for both the vortioxetine and the placebo group. The self-reported test sample of European ancestry participants suffering from depression or bipolar disorder identified 642 vortioxetine-treated participants based on the AESES questionnaire. In the statistical analysis, PRSs for treatment response, diseases, and symptom traits were calculated for everyone in both samples. Vortioxetine and placebo response association with these PRSs were estimated.
